1. Report Introduction 2. Coronary Artery Disease (CAD) Overview 3. Pipeline Therapeutics • An Overview of Pipeline Products for Coronary Artery Disease (CAD) 4. Comparative Analysis 5. Products in Clinical Stage 5.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities 6. Products in Pre-Clinical and Discovery Stage 6.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities 7. Therapeutic Assessment • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type 8. Inactive Products 8.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities Appendix Report Methodology Consulting Services Disclaimer About DelveInsight

Table 1: Total Products for Coronary Artery Disease (CAD) Table 2: Products in Clinical Stage Table 3: Products in Non-clinical Stage Table 4: Assessment by Route of Administration Table 5: Assessment by Stage and Route of Administration Table 6: Assessment by Molecule Type Table 7: Assessment by Stage and Molecule Type Table 8: Inactive Products Figure 1: Total Products for Coronary Artery Disease (CAD) Figure 2: Products in Clinical Stage Figure 3: Products in Non-clinical Stage Figure 4: Assessment by Route of Administration Figure 5: Assessment by Stage and Route of Administration Figure 6: Assessment by Molecule Type Figure 7: Assessment by Stage and Molecule Type Figure 8: Inactive Products

Akcea Therapeutics Inc Amarantus Bioscience Holdings Inc AnGes MG Inc Arena Pharmaceuticals Inc Ascendia Pharmaceuticals LLC AstraZeneca Plc Athera Biotechnologies AB Bayer AG Biscayne Pharmaceuticals Inc Capricor Therapeutics Inc Cardiome Pharma Corp CardioVascular BioTherapeutics Inc Cerenis Therapeutics Holding SA CSL Ltd Esperion Therapeutics Inc & list continues...